Amphastar Pharmaceuticals, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Jack Y. Zhang (CEO) and William J. Peters (CFO) issued standard Sarbanes-Oxley Section 302 and 906 certifications on August 6, 2026 for the quarterly report ended June 30, 2026. Both officers attest that financial statements fairly present the company's condition and that disclosure controls and internal financial reporting controls are effective. No material weaknesses, deficiencies, or fraud are disclosed.
Why this rating
Routine SOX certifications. No substantive business information disclosed; standard quarterly regulatory filing requirement.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.